A Look Ahead to ACC 2022: Late-Breaking Clinical Trials in Lipid Management

Erin D. Michos, MD, MHS

April 04, 2022

Erin D. Michos, MD, MHS, shares a preview of the late-breaking clinical trials that she is looking forward to at the American College of Cardiology 2022 Scientific Session and Expo in Washington, DC, on April 2-4. First, Dr Michos anticipates the results of the phase 1 APOLLO trial that will be presented by Steven Nissen, MD, which measures the efficacy of a short-interfering RNA targeting lipoprotein (a).

Next, Dr Michos looks at the forthcoming PACMAN-AMI trial, presented by Lorenz Raber, MD, which looks at coronary plaque composition change with alirocumab treatment and its effects on a statin.

Last, Dr Michos awaits the results of a secondary analysis, which she participated in, from the pooled FIDELITY study results of the large phase 3 trials FIDELIO-DKD and FIGARO-DKD, which investigated finerenone, a novel RNA, in patients with type 2 diabetes and chronic kidney disease.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: A Look Ahead to ACC 2022: Late-Breaking Clinical Trials in Lipid Management - Medscape - Apr 04, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.